research Re: Can Long-Term LUTS/BPH Pharmacological Treatment Alter the Outcomes of Surgical Intervention?
Long-term medication for enlarged prostate might not clearly affect the timing or outcomes of later surgery.
Search
for
Sort by
Research
150-180 / 384 results 
research Further research needed if finasteride is to become standard of care for frontal fibrosing alopecia (FFA)
More research needed to confirm finasteride as standard treatment for FFA.
research Characterization and Management of Androgenetic Alopecia in Transgender and Gender-Diverse Individuals: A Narrative Review
Personalized hair loss treatments are needed for transgender individuals, but more research is required.
research Post-finasteride syndrome: survey of dermatologists from the Spanish Hair and Nail Disorders Group
Most dermatologists think post-finasteride syndrome is rare, possibly psychiatric, and needs more research.
research Estimating the Effect of Finasteride on Kallikrein Marker Levels in Blood and the Use of Converted Markers in the Four-Kallikrein Model
Finasteride improves prostate cancer prediction by adjusting kallikrein marker levels.
research Oral finasteride use and sexual adverse events: signal detection from disproportionality analyses of data from the United States Food and Drug Administration Adverse Event Reporting System
Oral finasteride may cause more sexual side effects than expected, possibly due to negative publicity and reporting bias.
research The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
research Nouvelles thérapeutiques dans la prise en charge de l’alopécie androgénétique
De nouvelles thérapies promettent de mieux traiter la perte de cheveux due à l'alopécie androgénétique.
research Risk of Estrogen-Driven Malignancies in Females on 5-alpha Reductase Inhibitors
Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
research LB891 Analysis of breast health outcomes in women on oral 5-alpha reductase inhibitors: A single-center retrospective cohort study
5-alpha reductase inhibitors don't increase breast cancer or benign breast disorder risk in women.
research The Frontal Fibrosing Alopecia Treatment Dilemma
Effective treatment guidelines for frontal fibrosing alopecia are still unclear.
research Finasteride and Dutasteride for the Treatment of Male Androgenetic Alopecia: A Review of Efficacy and Reproductive Adverse Effects
Finasteride and Dutasteride can improve hair growth in male baldness but may cause temporary sexual dysfunction and possibly affect fertility.
research Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
research PD49-02 MEDICATIONS MOST COMMONLY ASSOCIATED WITH ERECTILE DYSFUNCTION: EVALUATION OF THE FOOD AND DRUG ADMINISTRATION NATIONAL PHARMACOVIGILANCE DATABASE
Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.
research Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
Finasteride reduces the need for prostate surgery but may increase the risk of depression and persistent sexual side effects.
research Editorial Comment
5-ARI therapy may help prevent prostate cancer progression.
research US Food and Drug Administration Warning Regarding Finasteride and Suicidal Ideation: What Should Urologists Know?
Urologists should screen for mental health issues before and during finasteride treatment.
research Dutasteride for Androgenetic Alopecia: Review Article
Dutasteride is effective for treating hair loss.
research 054 Post Finasteride Syndrome: Guess Who-Demographics from FDA Database
Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
research Post-Finasteride Syndrome (PFS) Update: Point/Counterpoint
Finasteride's link to health issues like male breast cancer, infertility, and prostate cancer needs more research through placebo-controlled trials to confirm.
research The impact of monotherapies for male androgenetic alopecia: A network meta‐analysis study
"Dutasteride 0.5 mg daily is the most effective treatment for male hair loss."
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research Using 5 alpha reductase inhibitors safely: What primary care physicians need to know
5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
research FINASTERIDE IN MODERN MEDICINE: THERAPEUTIC APPLICATIONS AND SYSTEMIC HEALTH IMPLICATIONS
Finasteride is effective for hair loss and prostate issues but may cause lasting side effects.
research 5α-Reductase Inhibitors and Chemoprevention: The PCPT and Beyond
5α-reductase inhibitors can reduce prostate cancer risk but may increase high-grade tumors, needing more research.
research BPH Medications May Increase Risk of Self-Harm, Depression
BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
research 5α- Reductase Inhibitors in Prostate Cancer: An Overview
5α-reductase inhibitors like Finasteride and Dutasteride may help manage prostate cancer by blocking testosterone conversion.
research Signal Detection of Depression and Suicidality Associated with Finasteride and Dutasteride: Updated Pharmacovigilance Evidence and Recommendations for Comprehensive Psychiatric Assessment
Finasteride may cause depression and suicidal thoughts, especially in young men.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.